---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-25-000045"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T16:52:21.142261+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio Q1 net loss $39.3M ($1.28/sh); rosnilimab Phase 2b RA data positive; $75M buyback authorized

## Summary
- Cash and investments $383M as of March 31, 2025, with cash runway through year-end 2027.
- Collaboration revenue $27.8M (up from $7.2M YoY), driven by Jemperli royalties and Vanda license.
- R&D expenses $41.2M, up from $37.0M YoY, primarily due to rosnilimab RA/UC and preclinical programs.
- Rosnilimab achieved highest-ever CDAI LDA response in 424-patient Phase 2b RA trial; six-month data surpassed competitors.
- Initial Phase 2 UC data for rosnilimab expected Q4 2025; GSK Jemperli $1B sales milestone still anticipated 2025/2026.

## SEC filing metadata
- accession: 0001370053-25-000045
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000045/0001370053-25-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000045/anab-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-25-000045
- JSON: https://secwatch.observer/filing/0001370053-25-000045.json
- Plain text: https://secwatch.observer/filing/0001370053-25-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.